Navigation Links
David Duncan Has a Prescription for American Health Care

BOSTON, Sept. 14 /PRNewswire/ -- The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion by David Ewing Duncan titled "One Man's Quest for Personalized Medicine." Over the course of one year, Duncan submitted himself to hundreds of tests that could predict and even prevent future illness.

One test made predictions about the health of Duncan's heart. By gathering data on his cholesterol levels, a heart CT scan, a genetic profile, and more, the test showed personalized predictions that were specific to Duncan's genes and physiology. One scenario showed Duncan's risk of heart attack at 70% over the next twenty years. That forecast changed dramatically if Duncan maintains his current weight instead of gaining the typical pound per year for a man over 40. With a steady weight, the risk fell to about 2 percent and with cholesterol lowering statins, Duncan's risk fell to zero.

"Many of these tests aren't ready for the general public, but they do give us an interesting glimpse into the future of medicine," said Duncan. "People are curious as to where this technology is going and we may never know unless we provide the organized push needed to learn more."

This specific test would cost nearly $1000 as demand increases but Duncan points out that a diagnostic cardiac catheterization can cost more than $25,000 and a heart bypass operation runs well over $85,000. The cost also has to be weighed against the 80 million Americans suffering from heart disease and the fact that nearly $450 billion was spent last year in direct and indirect costs for treatment of heart disease.

"David Duncan's journey through the American Health care system as a healthy person illustrates one of the major problems facing the American health care system today. That is, as health care professionals we recognize that it is imperative to identify patients who are at risk for developing heart disease, and then implement personalized strategies to reduce this risk," said Dr. Douglas Mann, HFSA President. "However, the upfront costs associated with screening large populations of patients with some of the emerging technologies may not be sustainable in the future. As we move forward in our efforts to prevent heart disease and heart failure, it will be essential to obtain outcomes data that identify the most cost effective and accurate strategies for identifying the patients who are at risk of developing heart disease and heart failure, as well as personalizing our approaches to these patients."

For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You can also follow the annual scientific meeting on Twitter #hfsa

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,500 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at

About David Ewing Duncan

David Ewing Duncan is an award-winning, best-selling author of seven books and numerous essays, articles and short stories; and a television, radio and film producer and correspondent. He is a Contributing Editor and Columnist for Conde Nast Portfolio, a Chief Correspondent for NPR Talk's "Biotech Nation," and a commentator for NPR's "Morning Edition". At UC Berkeley he is the Director of the Center for Life Science Policy and a Visiting Researcher at the Graduate School of Journalism. David's newest book, Experimental Man: What one man's body reveals about his future, your health, and our toxic world, is available now. More information can be found at

SOURCE The Heart Failure Society of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Delcath Systems, Inc. Appoints David McDonald Chief Financial Officer
2. David Blumenthal and Aneesh Chopra Give Keynote Addresses at AMIAs Conference on Anticipating and Addressing Unintended Consequences of HIT and Policy
3. Allied Worlds David Bell to Present as Keynote Speaker at 2009 Entrepreneurial Insurance Symposium
4. Pro Quarterback David Garrard Aims to Score Big For Crohns Disease During the 2009 Football Season
5. Health Expert Dr. David Friedman Reveals Which Sweeteners Are Best
6. Dr. David Okrongly Appointed CEO of Quanterix Corporation
7. Jackson & Coker Names David Booher Vice President of Emergency Medicine Recruitment
8. Phoenix Cardiovascular Surgeon, David J. Caparrelli, M.D. Becomes Member of the Society for Vascular Surgery
9. Re-Envision Your Look: Dr. David Whiteman Suggests Breast Revision Surgery as Solution for Women Dissatisfied with Prior Procedures
10. Huntsville, Alabama Plastic Surgeon David L. Durst, MD Comments on Silicone Breast Implants after Nearly 3 Years on the Open Market
11. Dr. David Williams Featured on
Post Your Comments:
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
Breaking Medicine Technology: